Key Points
- CEO Lisa Ricciardi purchased 9,175 shares at $1.10 on April 16 (≈$10,093), raising her holdings to 1,715,851 shares—a 0.54% increase in her position.
- The company is a clinical-stage biopharma developing CT1812, an oral sigma-2 receptor antagonist for Alzheimer's disease that is currently being evaluated in multiple Phase 2 studies across North America and Europe.
- Shares trade around $1.12 with a 52-week range of $0.22–$3.83 and a market cap of about $100M; the company posts negative earnings (consensus -$0.31 FY) and has a MarketBeat consensus rating of Moderate Buy with an average target of $3.33.
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi acquired 9,175 shares of the company's stock in a transaction on Thursday, April 16th. The stock was acquired at an average price of $1.10 per share, with a total value of $10,092.50. Following the acquisition, the chief executive officer owned 1,715,851 shares in the company, valued at approximately $1,887,436.10. This trade represents a 0.54% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Cognition Therapeutics Stock Performance
NASDAQ CGTX opened at $1.12 on Tuesday. Cognition Therapeutics, Inc. has a fifty-two week low of $0.22 and a fifty-two week high of $3.83. The stock has a 50 day simple moving average of $1.03 and a two-hundred day simple moving average of $1.36. The stock has a market cap of $100.07 million, a P/E ratio of -3.39 and a beta of 1.39.
Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.04. Sell-side analysts predict that Cognition Therapeutics, Inc. will post -0.31 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. grew its holdings in shares of Cognition Therapeutics by 34.7% during the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company's stock worth $40,000 after acquiring an additional 7,641 shares during the period. Bryn Mawr Trust Advisors LLC grew its holdings in shares of Cognition Therapeutics by 69.1% during the 3rd quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company's stock worth $53,000 after acquiring an additional 16,129 shares during the period. Jones Financial Companies Lllp purchased a new position in shares of Cognition Therapeutics during the 3rd quarter worth approximately $25,000. Essex Financial Services Inc. purchased a new position in shares of Cognition Therapeutics during the 4th quarter worth approximately $27,000. Finally, Gamco Investors INC. ET AL purchased a new position in shares of Cognition Therapeutics during the 3rd quarter worth approximately $27,000. Hedge funds and other institutional investors own 43.35% of the company's stock.
Analysts Set New Price Targets
CGTX has been the subject of several research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Cognition Therapeutics in a report on Friday, March 27th. raised shares of Cognition Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 3rd. Finally, Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of Cognition Therapeutics in a research report on Friday, March 27th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $3.33.
Get Our Latest Research Report on CGTX
Cognition Therapeutics Company Profile
(
Get Free Report)
Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer's disease. The company's lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer's disease.
CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer's disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
